Aspen API DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Corporate Presentation

ISO 45001:2018

ISO 14001:2015

Ecovadis Certificate

Peptide Development and Manufacturing Capabilities

Green Continuous LPPS

GMP Certificate 2023

Green Answer to Peptide Synthesis

Your Personal API Partner

Click the button for full data set

Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS)

Sustainable APIs Manufacturing 2022

DATA COMPILATION #PharmaFlow

Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17 13 37 Taiwan 9 6 5 4 24 Switzerland 15 4 4 23 France 16 6 22 Japan 18 1 19 United Kingdom 12 1 2 15 Mexico 9 1 1 11 Ireland 5 5 1 11 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years.

Impressions: 14650

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 4653

COMPANY BIO #AboutSupplier

Overview of high potency APIs or HPAPI contract manufacturing services & more on Aspen API's CDMO services for cytotoxic HPAPIs on PharmaCompass.

Overview of high potency APIs or HPAPI contract manufacturing services & more on Aspen API's CDMO services for cytotoxic HPAPIs on PharmaCompass.Q1. What is a highly potent API (HPAPI)?Highly potent active pharmaceutical ingredient (HPAPI) is a compound that elicits a biological response at a much smaller dose, such as a daily therapeutic dose of <10 mg. High potency drugs have the ability to bind selectively at low doses to specific receptors or inhibit specific enzymes as part of cancer or hormonal therapies.High-potency APIs (HPAPIs) require multi-step processes or semi-synthesis along with special handling requirements due to toxicity. HPAPI development and production require specialized considerations in facility design, equipment, operation and process safety to achieve the requisite level of containment. It also presents major handling challenges for innovators and manufacturing companies.High-potency APIs (HPAPIs) are becoming increasingly popular and companies are now looking for flexible containment solutions to help address their needs. However, if the current HPAPI development continues to show more efficacy, high potent API is likely to become one of the most dominant areas in the industry. High potency API (HPAPI) is prominent in oncology research and hence represents an increasingly significant share of the pharmaceutical drug pipeline.Because a growing number of pharmaceutical products contain highly potent active pharmaceutical ingredients (HPAPI) , demand for the production of HPAPIs has increased. Estimates suggest the global HPAPI market will register a strong growth over the next 5-10 years. In addition to cancer, highly potent API (HPAPI) is being used in hormonal imbalance drugs, cardiovascular drugs, central nervous system drugs and musculoskeletal drugs.The challenges in HPAPI manufacturing have also increased, along with investments, in terms of specialized containment areas and procedures to prevent personnel and environmental exposure. A pharmaceutical CDMO has the capability to offer highly potent small molecule development services and HPAPI Contract Manufacturing Services.Integrated CDMOs have capabilities to offer both production & development services for highly potent APIs (HPAPIs), and to scale-up for HPAPI (highly potent API) development from lab quantities to large-scale volumes. The main advantage of outsourcing HPAPI contract manufacturing services is that it eliminates the need to invest in costly containment infrastructure that can also be difficult to engineer, install and maintain and it can offer HPAPIs, ADCs, highly potent small molecule development services along with manufacturing.Q2. How are the different containment challenges addressed for high-potency APIs (HPAPIs)?HPAPI can be a small-molecule, a biologic, or a hybrid of two molecules, such as an antibody-drug conjugate that links a cytotoxic small molecule to a monoclonal antibody. The cytotoxic nature of highly potent APIs presents significant challenges in terms of safe handling and containment during process scale-up and development, clinical and large-scale production of highly potent APIs (HPAPIs). Hence, HPAPIs require heavy investments for the implementation of specialized containment facilities.Additionally, the cGMP manufacturing of high-potency active pharmaceutical ingredients (HPAPIs) requires an isolated environment that is equipped with isolators and cleanrooms. Working with an experienced pharmaceutical outsourcing organization such as a CMO or CDMO for contract manufacturing of highly potent compounds can help eliminate challenges like investing in expensive infrastructure and the cost of training staff for the production of a highly potent API (HPAPI). Such outsourcing organizations can also offer highly potent intermediates and active pharmaceutical ingredients, ADCs, biologics, large molecule, highly potent small molecule development services along with other contract manufacturing services.HPAPI containment challenges can be handled through the following ways: One of the largest areas for consideration is equipment. All HPAPI handling and development systems must be tested and verified to meet the necessary isolation requirements while developing and manufacturing high potent active pharmaceutical ingredients (HPAPI). The capability of equipment, systems and procedures to contain and isolate materials under expected operating conditions must be verified as it is a critical component of the overall HPAPI handling and development program. There must be a close evaluation of the compound for potential toxicity, potency and hazards while developing and manufacturing high potent active pharmaceutical ingredients (HPAPI). By applying rigorous engineering controls within the process scale-up and development, high-quality high potent active pharmaceutical ingredients (HPAPIs) can be produced without adverse effects. Specialized considerations in facility design, equipment, operation and process scale-up and development as well as safety are needed to achieve the desired level of containment of high potency API (HPAPI) and drug products. It is necessary to carry out a careful assessment of the hazards posed by each product, reagent and intermediate involved in the synthesis before cGMP manufacturing. To identify the exposure potential, factors including the quantity of material to be handled, the percentage of high potent active pharmaceutical ingredients (HPAPI) and any excipient components, along with the task duration should be considered.Q3. How do contract development and manufacturing organizations (CDMOs) help in the production of HPAPIs?High potency active pharmaceutical ingredient (HPAPI) is a growing area for pharmaceutical manufacturers. Around a third of all drugs in the pharmaceutical pipeline are categorized as high potency active pharmaceutical ingredients (HPAPIs). However, HPAPIs have strict handling requirements that require high capital investment and specialized personnel to develop. Producing ADC, which requires conjugation of a small molecule to a large biomolecule, is even more challenging.Highly potent compounds present numerous challenges in terms of preventing cross-contamination during developing and manufacturing high potent active pharmaceutical ingredients (HPAPIs). As a result, many HPAPI investigators turn to contract development and manufacturing organizations (CDMOs) and CMOs who have the facilities, equipment and personnel in place to take their projects through HPAPI development and manufacturing.While many CDMOs have made significant investments in their highly potent API (HPAPI) capabilities over the last two decades to provide reliable support throughout all project stages, including process scale-up and development, clinical and commercial cGMP manufacturing. A pharmaceutical CMO or CDMO has capabilities such as isolator design, laboratory design and containment practices that are critical for safe HPAPI and cytotoxic drugs manufacturing.Most HPAPIs in clinical development are outsourced to contract development and manufacturing organizations (CDMOs) that have the necessary process expertise, qualified facilities for the production of highly potent intermediates and active pharmaceutical ingredients.Points to consider while choosing a CDMO for HPAPI development and Manufacturing: Any CDMO considered as an HPAPI production partner should have experience in the field and a long track record of successfully manufacturing and handling potent compounds, including highly potent intermediates and active pharmaceutical ingredients. There should be clear evidence of regulatory expertise and a positive compliance history. The appropriate containment strategy should be selected for HPAPI (highly potent API) development and manufacturing based on scale. CDMO facilities should include cGMP compliant isolator systems (OEL 0.1 µg/m³) for high-potent raw materials, intermediates and APIs. The ability of a CDMO to support projects for developing and manufacturing high potent active pharmaceutical ingredients (HPAPIs) through commercialization as well as extensive analytical capabilities are quite important. These factors are indicators of long-term commitment to HPAPI production. CDMO facilities should be designed with containment strategies based primarily on engineering controls, such as equipment and procedures, ventilation, chemical contaminants, etc. and administrative solutions (processes and PPE) as secondary measures. Also, rigorous safety, health and environmental (SHE) practices, along with Occupational Exposure Band (OEB) and Occupational Exposure Limit (OEL) based controls, need to be established to protect workers, materials, machines and the environment.Q4. What HPAPI manufacturing services does Aspen API offer?Aspen API is a contract development & manufacturing organization (CDMO) that provides development, upscaling and commercial manufacturing for complex high potency API (HPAPI), peptide APIs, oncology APIs, cytotoxic APIs, along with narcotics and other established APIs. Aspen API has over 58 high-quality APIs available, ranging from high potency, oncology, peptides, narcotics, analgesics and botanical extraction to biochemical APIs.At Aspen API, CDMO or CMO API projects are in excellent hands. Aspen API can add value to the client's projects and collaborate with the client to ensure success. It has a century-long history in development, upscaling and commercially manufacturing complex high potency APIs (HPAPIs), oncology APIs, peptides, along with narcotics and other established APIs. Whether the project is for a New Chemical Entity (NCE) or a process for (re-)designing (intermediate) API, Aspen API is the perfect partner to manage projects - from the development phase to the commercial implementation. Aspen API adds expertise, innovation, compliance, registration and partnership to the client's projects.Aspen API's facilities are successfully inspected and approved by regulatory authorities such as US FDA, EDQM, PMDA and others. It has expertise in manufacturing high potency API (HPAPI) and oncology APIs. Supported by a robust quality system, Aspen API produces high-quality products, which are manufactured in compliance with cGMP, ICH and safety, health and environmental (SHE) regulations.At both Aspen Oss and Fine Chemicals Corporation, high potent APIs are produced in units with OEB 4 and 5 classifications. Aspen API has a long history of working with Occupational Exposure Limit (OEL) levels, from as low as 0.01 µg/m³. Its heritage in manufacturing complex highly potent active pharmaceutical ingredients (HPAPIs) has enabled Aspen API to establish world class systems and procedures for safe HPAPI handling and development. At Fine Chemicals Corporation, high potent active pharmaceutical ingredients (HPAPI) and cytotoxic product manufacturing is carried out in a dedicated purpose-built facility.Manufacturing capabilities Manufacturing under full cGMP Batches ranging from 1 kg to 500 kg active pharmaceutical ingredient (API) Commercial manufacturing ranging from 100 to 10.000 liters Best-in-class cleaning procedures Isolator technology for micronization and milling of Occupational Exposure Band (OEB) 4 and 5 compounds for HPAPI Manufacturing Grade D clean room manufacturing for weighing and dispensingIntegration in processes In-house safety, health and environmental (SHE) specialists with expert knowledge Well-trained staff and best-in-class safety protocols Safety assessments using calorimetry on processes, intermediates and active pharmaceutical ingredients (APIs) All intermediates and active pharmaceutical ingredients (APIs) on site assigned to Occupational Exposure Band (OEB) category ISO14001 and ISO 45001 certified

Impressions: 2599

NEWS #PharmaBuzz

Yes, hashtag#Estradiol is added to our list of approved CADIFA’s

30 Sep 2025

// PRESS RELEASE

Leader in CADIFA approval

28 Feb 2025

// PRESS RELEASE

Saving costs & producing sustainably, success Femke’s internship

11 Feb 2025

// PRESS RELEASE

Nieké van Gils, Jr. scientist at Aspen API on international women’s day.

07 Mar 2024

// PRESS RELEASE

Gold Medal for Aspen API in EcoVadis Evaluation

31 Oct 2023

// PRESS RELEASE

Fine Chemicals Corporation facility in Cape Town, South Africa was inspected by the PMDA.

31 Oct 2023

// PRESS RELEASE

ALL APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

16-alpha-hydroxyprednisolone

Netherlands

Aspen API

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 8855

Submission : 1990-11-26

Status : Active

Type : II

02

Azathioprine

South Africa

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Fine Chemicals Corporation PTY Ltd

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 10119

Submission : 1993-02-19

Status : Active

Type : II

03

Azathioprine (process 3)

Netherlands

Aspen API

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 34647

Submission : 2020-09-18

Status : Active

Type : II

04

Baclofen

Netherlands

Aspen API

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 6421

Submission : 1986-06-18

Status : Active

Type : II

05

Baclofen (process 2)

Netherlands

Aspen API

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35224

Submission : 2020-10-16

Status : Active

Type : II

06

Benztropine Mesylate

Netherlands

Aspen API

GDUFA

DMF Review : Complete

Rev. Date : 2012-10-25

Pay. Date : 2012-12-19

DMF Number : 6914

Submission : 1987-04-09

Status : Active

Type : II

07

Budesonide

Netherlands

Aspen API

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 10493

Submission : 1993-09-23

Status : Active

Type : II

08

Buprenorphine Hydrochloride

Netherlands

Aspen API

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 7099

Submission : 1987-08-06

Status : Active

Type : II

09

Conjugated Estrogens Type Cn

Netherlands

Aspen API

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 34883

Submission : 2020-06-09

Status : Active

Type : II

10

Danaparoid Sodium

Netherlands

Aspen API

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 10519

Submission : 1993-10-08

Status : Inactive

Type : II

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

01

Azathioprine, Process 3

Netherlands

Aspen API

Certificate Numbers : R1-CEP 2017-171 - Rev 00

Status : Valid

Issue Date : 2023-02-13

Type : Chemical

Substance Number : 369

02

Budesonide

Netherlands

Aspen API

Certificate Numbers : R1-CEP 2016-043 - Rev 01

Status : Valid

Issue Date : 2023-02-10

Type : Chemical

Substance Number : 1075

03

Budesonide, Budesonide ZS

Netherlands

Aspen API

Certificate Numbers : R0-CEP 2021-491 - Rev 01

Status : Valid

Issue Date : 2023-02-10

Type : Chemical

Substance Number : 1075

04

Codeine phosphate hemihydrate

South Africa

Fine Chemicals Corporation PTY Ltd

Certificate Numbers : R1-CEP 2010-052 - Rev 01

Status : Valid

Issue Date : 2019-01-18

Type : Chemical

Substance Number : 74

05

Codeine phosphate hemihydrate, Process I...

South Africa

Fine Chemicals Corporation PTY Ltd

Certificate Numbers : CEP 2021-385 - Rev 01

Status : Valid

Issue Date : 2024-02-06

Type : Chemical

Substance Number : 74

06

Desmopressin

Netherlands

Aspen API

Certificate Numbers : R1-CEP 1999-165 - Rev 05

Status : Valid

Issue Date : 2016-03-31

Type : Chemical

Substance Number : 712

07

Desogestrel

Netherlands

Aspen API

Certificate Numbers : R1-CEP 2009-300 - Rev 00

Status : Valid

Issue Date : 2016-03-16

Type : Chemical

Substance Number : 1717

08

Estradiol hemihydrate

Netherlands

Aspen API

Certificate Numbers : R2-CEP 1995-001 - Rev 03

Status : Valid

Issue Date : 2014-01-30

Type : Chemical

Substance Number : 821

09

Estradiol valerate

Netherlands

Aspen API

Certificate Numbers : CEP 2009-171 - Rev 02

Status : Valid

Issue Date : 2025-04-25

Type : Chemical

Substance Number : 1614

10

Estriol

Netherlands

Aspen API

Certificate Numbers : R1-CEP 1999-179 - Rev 05

Status : Valid

Issue Date : 2017-03-29

Type : Chemical

Substance Number : 1203

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

VMF

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

01 Aspen API

Netherlands

Lead Product(s) : Acetylcysteine,Inapplicable

Therapeutic Area : Pharmacology/Toxicology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Glenmark Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Acquisition

Glenmark Acquires & Launches Acetylcysteine Injection 6gm/30mL Single-Dose Vials

Details : Glenmark has acquired generic version of Acetadote (acetylcysteine) injection from Aspen Pharma. It is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury.

Product Name : Acetadote-Generic

Product Type : Miscellaneous

Upfront Cash : Undisclosed

March 03, 2025

02 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : Tirzepatide,Inapplicable

Therapeutic Area : Endocrinology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Eli Lilly

Deal Size : Inapplicable

Deal Type : Inapplicable

Aspen Announces Local Availability of Lilly’s Mounjaro

Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.

Product Name : Mounjaro

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

December 20, 2024

03 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : Octreotide Acetate,Inapplicable

Therapeutic Area : Endocrinology

Highest Development Status : Approved FDF

Recipient : Sandoz B2B

Deal Size : $99.9 million

Deal Type : Agreement

Aspen Concludes Two Significant Agreements with Sandoz for China and Europe

Details : The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

Product Name : Sandostatin LAR Depot

Product Type : Peptide, Unconjugated

Upfront Cash : Undisclosed

December 04, 2023

04 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : Pneumococcal Polysaccharide Conjugate Vaccine,Inapplicable

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Gates Foundation

Deal Size : $30.0 million

Deal Type : Funding

Aspen, CEPI And The Bill & Melinda Gates Foundation Expand Commitments To Improve Access To Vaccin...

Details : PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.

Product Name : Pneumosil

Product Type : Vaccine

Upfront Cash : Undisclosed

December 12, 2022

05 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : 10-Valent Pneumococcal Polysaccharide Conjugate Vaccine,Inapplicable

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Serum Institute of India

Deal Size : Undisclosed

Deal Type : Collaboration

Aspen Concludes a Collaboration Agreement to Manufacture and Make Available Four Aspen-Branded Vac...

Details : PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countrie...

Product Name : Undisclosed

Product Type : Vaccine

Upfront Cash : Undisclosed

August 31, 2022

06 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : Atropine Sulfate,Inapplicable

Therapeutic Area : Ophthalmology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children

Details : EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.

Product Name : Eikance

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 18, 2022

07 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : Triptorelin Pamoate,Inapplicable

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Debiopharm

Deal Size : Undisclosed

Deal Type : Partnership

Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa

Details : Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer pat...

Product Name : Trelstar

Product Type : Hormone

Upfront Cash : Undisclosed

February 01, 2022

08 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : Ad26.COV2.S,Inapplicable

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Johnson & Johnson

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

Details : The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.

Product Name : Undisclosed

Product Type : Vaccine

Upfront Cash : Undisclosed

November 30, 2021

09 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : Esomeprazole Magnesium,Inapplicable

Therapeutic Area : Gastroenterology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Acino Pharma

Deal Size : $119.4 million

Deal Type : Acquisition

Acino Acquires Selected Aspen Brands in South Africa

Details : The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.

Product Name : Trustan

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 22, 2021

10 Aspen Pharmacare Holdings

South Africa

Lead Product(s) : Conjugated Estrogens,Inapplicable

Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Avion Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Partnership

Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals

Details : Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy d...

Product Name : Cenestin

Product Type : Miscellaneous

Upfront Cash : Undisclosed

November 12, 2020